MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jconrel.2026.114991

Медицинская библиотека · Journal of controlled release : official journal of the Controlled Release Society · 2026

Delivery of a ZBP1 agonist enhances radiotherapy-induced antitumour immunity in hepatocellular carcinoma.

Liu Hui, He Qiao, Wang Dong-Xu, Liu Jingru, Qu Ying, Zhang Daolin, Sun Pengfei, Li Han, Peng Shengxuan, Li Ruizhe, Dong Zhaoru, Zou Jianhua, Liu Jie, Li Tao

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Hepatocellular carcinoma (HCC) shows limited responsiveness to immune checkpoint inhibitors (ICIs), largely because many tumors remain poorly inflamed and refractory to effective antitumour immunity. Here, we identify Z-DNA-binding protein 1 (ZBP1) as an immune-associated determinant of therapeutic responsiveness in HCC and explore its potential as a target for radio-immunotherapy sensitization. Integrative analysis of necroptosis-related genes and immunotherapy-response datasets revealed that high ZBP1 expression was associated with favourable survival, enhanced antigen-presentation signatures, increased immune-cell infiltration, and improved immunotherapy benefit. Functionally, basal ZBP1 expression alone had limited effects on tumor-cell behavior, whereas pharmacological activation of ZBP1 markedly enhanced therapeutic responsiveness. Mechanistically, ZBP1 activation promoted necroptosis-associated signaling and amplified IFN and STING-related innate immune activation. Radiotherapy further upregulated ZBP1, providing a mechanistic basis for combination treatment. To enable tumor-directed delivery, we developed a glypican-3 (GPC3)-targeted liposomal nanoplatform co-loaded with the ZBP1 agonist CBL0137 and gold nanoparticles (CBL-Au@Lip). CBL-Au@Lip exhibited stable physicochemical properties, acceptable biosafety, and enhanced tumor-associated accumulation. In vitro, CBL-Au@Lip cooperated with radiotherapy to suppress malignant phenotypes and strengthen immune-related signaling. In orthotopic HCC models, triple therapy comprising radiotherapy, anti-PD-L1 antibody (aPD-L1), and CBL-Au@Lip achieved superior tumor control, increased intratumoral T-cell infiltration and cytotoxic activation, and induced durable antitumour immune memory. Importantly, this therapeutic benefit was retained in a fibrosis-associated HCC model, although no obvious antifibrotic effect was observed. Together, these findings identify targeted ZBP1 activation as a promising strategy to enhance radio-immunotherapy and support further translational development of CBL-Au@Lip-based combination therapy in HCC.

Для цитирования: Liu Hui, He Qiao, Wang Dong-Xu, Liu Jingru, Qu Ying, Zhang Daolin, Sun Pengfei, Li Han, Peng Shengxuan, Li Ruizhe, Dong Zhaoru, Zou Jianhua, Liu Jie, Li Tao. Delivery of a ZBP1 agonist enhances radiotherapy-induced antitumour immunity in hepatocellular carcinoma.. Journal of controlled release : official journal of the Controlled Release Society. 2026. DOI: 10.1016/j.jconrel.2026.114991.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.